Position in CELC
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$107,323,065
-$38,755,133 QoQ
Shares Held
1,025,837
-19.8% QoQ
Ownership
2.10%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#16
of 274 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in CELC Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026PRICE T ROWE ASSOCIATES INC /MD/ holds $17,555,651,841 across 303 Biotechnology names. CELC ranks #44 (0.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ARGX |
Argenx SE
|
2,678,047 | $2,484,611,664 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,529,709 | $953,834,749 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
1,728,421 | $858,558,562 | |
| 4 | KYMR |
Kymera Therapeutics, Inc.
|
7,112,980 | $815,645,416 | |
| 5 | RPRX |
Royalty Pharma plc
|
11,193,657 | $627,628,347 | |
| 6 | RVMD |
Revolution Medicines, Inc.
|
2,969,853 | $447,655,945 | |
| 7 | MRNA |
Moderna, Inc.
|
5,589,560 | $391,436,886 | |
| 8 | SRRK |
Scholar Rock Holding Corp
|
6,794,837 | $373,716,035 |
All Filings in CELC
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $107,323,065 | 1,025,837 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $146,078,198 | 1,279,816 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | $123,705,626 | 1,240,281 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $29,548,905 | 598,156 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $202,733 | 15,186 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | $142,874 | 14,132 | Shares | Defined | 2025-05-14 | |
| 2024-12-31 | $166,517 | 12,721 | Shares | Defined | 2025-02-14 | |
| No filing history on record for this holder in this stock. | ||||||